Popular Articles
Teeth Whitening

Low Medicare Reimbursement Rates Hurt Hospitals In Iowa And California
Low Medicare reimbursement rates are not keeping up with costs at hospitals in Iowa and California while a grant helps boost Medicare enrollment in Missouri.
generic viagra online
AVMA Reaffirms Commitment To Host Pike Place Fish Market Educational Program
The American Veterinary Medical Association (AVMA) announced that it is moving forward with its original plan to host an educational, team-building program by the Pike Place Fish Market"s world-renowned fishmongers at its annual convention, which will be held in Seattle, Wash., July 11-July 14.
News of the day
Supreme Court Should Be 'Reined In' To Return Power To Legislative Branch, NYT Columnist Writes
Although Supreme Court nominee Sonia Sotomayor"s confirmation hearings are more than a month away, "it"s easy to predict how they will go," New York Times columnist Ross Douthat writes. Douthat predicts that Senate Judiciary Committee members "will attempt to divine Sotomayor"s position on a variety of controversial topics," such as abortion rights, and in "a series of polite, evasive answers, the nominee will feign a studious neutrality on almost every issue that could come before her during what"s likely to be decades as one of the most powerful women in the world." According to Douthat, the "deeper stakes" that likely will be ignored are that "Sotomayor will be joining a high court that"s gradually become a kind of extra legislative body." He cites research from Harvard Law School professor Jed Shugerman showing that the court over roughly the past 50 years has invalidated both state and federal statutes at an unprecedented rate. Douthat also points to data from Evan Caminker of the University of Michigan showing that in one eight-year period, the court invalidated 16 federal laws in 5-4 votes, something that occurred only 25 times in the previous two centuries. Douthat writes that "settling so many vexing controversies with 5-to-4 votes -- effectively making Anthony Kennedy the nation"s philosopher king -- is an awfully poor way to run a republic."Douthat continues that the "modern court"s most enduringly controversial power grabs -- with Roe v. Wade leading the way -- were usually the work of liberal justices" but that "in practice, the main divide between liberal and conservative judges tends to be over the responsibilities of the federal government, not judicial activism per se." He writes, "There are bipartisan ways that the Court could be reined in, and the legislative branch reinvigorated," including the idea of a supermajority rule that would require a 6-3 vote to overturn federal legislation. This idea "might spur the court toward greater consensus, and perhaps greater modesty as well," according to Douthat. Another possibility would be to implement 12-year term limits, he says. Douthat concludes that these suggestions would not "reduce the Supreme Court"s power directly, but it would help us see the court for what it has become -- a deeply political institution, as fallible as any other, and answerable, when all is said and done, to us" (Douthat, New York Times, 6/2).
Health Insurance

FDA Approves First Maintenance Drug Therapy For Advanced Lung Cancer

The U.S. Food and Drug Administration has approved Alimta (pemetrexed), the first drug available for maintenance therapy of advanced or metastatic lung cancer. Patients with cancer often receive maintenance therapy to prevent the disease from progressing after their tumor has shrunk or the disease has stabilized in response to chemotherapy. Alimta disrupts metabolic processes that are dependent on the B-vitamin folate, a necessary ingredient for cell replication. "This drug represents a new approach in the treatment of advanced non-small cell lung cancer," said Richard Pazdur, M.D., director, Office of Oncology Drug Products in the FDA"s Center for Drug Evaluation and Research. "Typically, patients whose tumors respond to chemotherapy do not receive further treatment after four-to-six chemotherapy cycles. This study demonstrates an advantage in overall survival in certain patients who received Alimta for maintenance therapy." Non-small cell lung cancer has several subtypes, including squamous cell, large cell, adenocarcinoma and mixed histology cancers. In a 600-patient clinical trial, people with predominantly squamous cell cancer did not benefit from Alimta. But those with other subtypes of non-small lung cancer survived an average 15.5 months following treatment compared with 10.3 months for patients who received an inactive substance (placebo). All patients in the study received standard medical care. Reported adverse events included damage to blood cells, fatigue, nausea, loss of appetite, tingling or numbness in the hands and feet, and skin rash. Alimta initially was approved in 2004 for the treatment of patients with mesothelioma, a cancer frequently related to asbestos exposure. The drug was later approved for the treatment of patients with non-small cell lung cancer whose disease worsened on prior chemotherapy drugs and also as an initial therapy for advanced non-small cell lung cancer. Alimta is manufactured by Eli Lilly & Co. of Indianapolis. U.S. Food and Drug Administration


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):